Avidity Biosciences Inc’s recent filing unveils that its Chief Medical Officer Hughes Steven George unloaded Company’s shares for reported $0.1 million on Aug 22 ’25. In the deal valued at $46.40 per share,2,208 shares were sold. As a result of this transaction, Hughes Steven George now holds 38,867 shares worth roughly $1.83 million.
Then, McCarthy Teresa sold 10,000 shares, generating $465,632 in total proceeds. Upon selling the shares at $46.56, the Chief Human Resources Officer now owns 97,130 shares.
Before that, TERESA MCCARTHY bought 45,000 shares. Avidity Biosciences Inc shares valued at $2,073,150 were divested by the Officer at a price of $46.07 per share.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 3.93% to $47.05. Over the last five days, the stock has gained 6.88%. Avidity Biosciences Inc shares have risen nearly 9.79% since the year began. Nevertheless, the stocks have risen 61.80% over the past one year. While a 52-week high of $56.00 was reached on 08/06/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 45.45, which if violated will result in even more drops to 43.84. On the upside, there is a resistance level at 48.07. A further resistance level may holdings at 49.09.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-08-15, dropping by -0.59 million shares to a total of 15.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 16.26 million shares. There was a decline of -3.75%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
